Source comparison
Comparative Analysis: Hexarelin vs Other Growth Hormone Secretagogues
Hexarelin 100–200 mcg per dose, 2–3× daily 300–500% above baseline 90–150 minutes Strong agonist (hunger suppression noted) High. Direct lipolytic signaling when fasted and paired with caloric deficit Ipamorelin 200–300 mcg per dose, 2–3× daily 200–350% above
This comparison does not assign a generated winner or score.
- Hexarelin
- 100–200 mcg per dose, 2–3× daily
- 300–500% above baseline
- 90–150 minutes
- Strong agonist (hunger suppression noted)
- High. Direct lipolytic signaling when fasted and paired with caloric deficit
- Ipamorelin
- 200–300 mcg per dose, 2–3× daily
- 200–350% above baseline
- 120–180 minutes
- Minimal cross-reactivity
- Moderate. Slower GH release curve, less pronounced FFA mobilization
- CJC-1295 (DAC)
- 1–2 mg per week (long-acting)
- Sustained 150–250% elevation
- 5–7 days per injection
- None
- Moderate. Elevated baseline GH but lacks pulsatile peaks that drive acute lipolysis
- GHRP-2
- 250–400% above baseline
- 90–120 minutes
- Moderate agonist (appetite increase common)
- Moderate-high. Effective but appetite stimulation complicates caloric restriction
- MK-677 (Ibutamoren)
- 10–25 mg orally, once daily
- 150–300% above baseline (sustained)
- 24 hours
- Strong agonist (significant appetite increase)
- Low-moderate. Elevated baseline GH but significant water retention and appetite stimulation offset fat loss
- Professional Assessment
- Hexarelin offers the highest acute GH pulse magnitude with the shortest duration, making it ideal for fat mobilization protocols when timed around fasted training. Ipamorelin is gentler with fewer side effects but requires higher doses. CJC-1295 DAC maintains elevated GH chronically but lacks the pulsatile peaks that drive lipolysis. GHRP-2 is comparable to hexarelin but the appetite stimulation is a practical liability. MK-677 is convenient (oral) but the appetite and water retention make it poorly suited for fat loss despite sustained GH elevation.